The Expression of width and Colour Plane in the Sur Karakul Lambs of Different Colours

The results of research into similar and distinctive features in the study of curl breadth and color consistency of karakul lambs of harsh diamond and silver coloration are presented in this article

Synthesis of new 2H-benzimidazole 1,3-dioxide derivatives analogous to separase inhibitor (Sepin-1)

© 2017, Pleiades Publishing, Ltd. New biologically active 2H-benzimidazole 1,3-dioxide derivatives, analogs of Sepin-1, have been synthesized starting from benzofuroxan. Electrophilic substitution of hydrogen in the 2H-benzimidazole ring occurs at different positions, depending on the electrophile nature

ASSESSMENT OF CRACKING RESISTANCE OF CELLULAR CONCRETE PRODUCTS UNDER MOISTURE AND CARBONISATION DEFORMATIONS WITH STRESS RELAXATION

Objectives. On the basis of the experimental, theoretical and field studies, an engineering calculation method was developed for assessing the cracking resistance of external enclosing constructions made of cellular concrete, with the maximum gradient development of moisture and carbonisation forced deformations along their thickness, taking into account the relaxation of the shrinkage stresses. In this regard, the aim of the work is to provide technological measures at the manufacturing stage in order to increase the operational cracking resistance of the construction's outer surface layers by reducing the moisture and carbonation shrinkage of cellular concrete by introducing a large or fine porous aggregate in calculated amounts.Methods. A number of analytical equations were applied to establish the dependence of the shrinkage of heavy concrete of conventional hardness on the amount of aggregate introduced and its elasticity modulus, water-cement ratio and cement consumption, as well as the concrete's moisture content.Results. Knowing the volumes of the structural aggregate and the cellular concrete mass, as well as their modulus of elasticity, the shrinkage reduction factor of the cellular concrete was calculated with the addition of a lightweight porous aggregate. Subsequently, the shrinkage deformations of concrete in the surface layer of the outer enclosing construction, maximising crack resistance due to moisture exchange and carbonation influences under operating conditions, were defined, taking into account the relaxation of tensile stresses due to creep of concrete.Conclusion. Theoretical calculations, based on the recommended method of assessing the cracking resistance of cellular concrete enclosing constructions under moisture exchange and carbonisation processes, taking into account the relaxation of shrinkage stresses, showed that in order to exclude the appearance of cracks in wall panels 280 mm thick made of 700 kg/m3 gas ash concrete with elasticity modulus of 2500 MPa, it is necessary to have 70-80% of keramzite or granulated slag, and 50-60% of stone crumb (granite or marble crushed stone) of the volume of cellular concrete in the surface layer of 30-50 mm

Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft

n/

Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT

Transplantation and immunomodulatio

Erosive-ulcerative lesions of the mucous membrane of the stomach and duodenum during therapy with 5-fluorouracil

Aim of the study was to improve the idea of the possibility of erosive and ulcerative lesions of the stomach and duodenum during treatment with 5-fluorouracil in patients with malignant tumors of the colon and rectosigmoid and the factors that aggravate their course, as well as to highlight the problem of prevention and treatment of gastrointestinal complications.Цель исследования – усовершенствование представления о возможности возникновения эрозивно-язвенных повреждений желудка и двенадцатиперстной кишки на фоне лечения 5-фторурацилом больных со злокачественными опухолями ободочной кишки и ректосигмоидного отдела и факторах, усугубляющих их течение, а также освещение проблемы профилактики и лечения гастроинтестинальных осложнений

Beta-thalassemia

Beta-thalassemias are a group of hereditary blood disorders characterized by anomalies in the synthesis of the beta chains of hemoglobin resulting in variable phenotypes ranging from severe anemia to clinically asymptomatic individuals. The total annual incidence of symptomatic individuals is estimated at 1 in 100,000 throughout the world and 1 in 10,000 people in the European Union. Three main forms have been described: thalassemia major, thalassemia intermedia and thalassemia minor. Individuals with thalassemia major usually present within the first two years of life with severe anemia, requiring regular red blood cell (RBC) transfusions. Findings in untreated or poorly transfused individuals with thalassemia major, as seen in some developing countries, are growth retardation, pallor, jaundice, poor musculature, hepatosplenomegaly, leg ulcers, development of masses from extramedullary hematopoiesis, and skeletal changes that result from expansion of the bone marrow. Regular transfusion therapy leads to iron overload-related complications including endocrine complication (growth retardation, failure of sexual maturation, diabetes mellitus, and insufficiency of the parathyroid, thyroid, pituitary, and less commonly, adrenal glands), dilated myocardiopathy, liver fibrosis and cirrhosis). Patients with thalassemia intermedia present later in life with moderate anemia and do not require regular transfusions. Main clinical features in these patients are hypertrophy of erythroid marrow with medullary and extramedullary hematopoiesis and its complications (osteoporosis, masses of erythropoietic tissue that primarily affect the spleen, liver, lymph nodes, chest and spine, and bone deformities and typical facial changes), gallstones, painful leg ulcers and increased predisposition to thrombosis. Thalassemia minor is clinically asymptomatic but some subjects may have moderate anemia. Beta-thalassemias are caused by point mutations or, more rarely, deletions in the beta globin gene on chromosome 11, leading to reduced (beta+) or absent (beta0) synthesis of the beta chains of hemoglobin (Hb). Transmission is autosomal recessive; however, dominant mutations have also been reported. Diagnosis of thalassemia is based on hematologic and molecular genetic testing. Differential diagnosis is usually straightforward but may include genetic sideroblastic anemias, congenital dyserythropoietic anemias, and other conditions with high levels of HbF (such as juvenile myelomonocytic leukemia and aplastic anemia). Genetic counseling is recommended and prenatal diagnosis may be offered. Treatment of thalassemia major includes regular RBC transfusions, iron chelation and management of secondary complications of iron overload. In some circumstances, spleen removal may be required. Bone marrow transplantation remains the only definitive cure currently available. Individuals with thalassemia intermedia may require splenectomy, folic acid supplementation, treatment of extramedullary erythropoietic masses and leg ulcers, prevention and therapy of thromboembolic events. Prognosis for individuals with beta-thalassemia has improved substantially in the last 20 years following recent medical advances in transfusion, iron chelation and bone marrow transplantation therapy. However, cardiac disease remains the main cause of death in patients with iron overload

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Background: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods: The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results: The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions: This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223)